Companies: 10,795·Total market cap: $144.5T

Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAMNYSEHealthcare

$28.00

+$0.02(+0.07%)

Market Cap$1.8B

P/E Ratio—

52W High$28.15

52W Low$6.55

Avg Volume2.0M

Open$27.99

Beta-2.36

Net Income Financials Revenue

Ambrx Biopharma Inc. (AMAM) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

AMAM · net income · updated Jun 9, 2026

Core profitability metrics

AMAM · net income · margin · TTM · CAGR

Net income was −$78.0M for FY2022 (fiscal year ending 2022-12-31), down 14.2% year-over-year. Net profit margin was -1053.7%.

FY2022 Net Income−$78.0M▼ -14.2% YoY

Trailing 12M (TTM)−$69.4Mtrailing 4 quarters sum

Net Profit Margin< −999%−$78.0M ÷ $7.4M

YoY Change-14.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · AMAM net income history · AMAM profit margin

Annual net income data

AMAM · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2022Loss−$78.0M▼ 14.2%-1053.7%$7.4M

FY2021Loss−$68.3M▼ 282.8%-916.0%$7.5M

FY2020Loss−$17.8M▲ +20.1%-130.5%$13.7M

FY2019Loss−$22.3M—-216.4%$10.3M

Net income vs peers (Healthcare)

AMAM vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Ambrx Biopharma Inc.YOU

AMAM

−$78.0M-14.2%-1053.7%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Ambrx Biopharma Inc. (AMAM) reported net income of −$78.0M for FY2022 (fiscal year ending 2022-12-31), down 14.2% year-over-year. The net profit margin was -1053.7% — meaning the company kept $-10.54 of every dollar of revenue as profit.

Ambrx Biopharma Inc. has not yet achieved annual profitability based on available data (4 fiscal years). The company has reported net losses across all available periods.

Ambrx Biopharma Inc.'s net profit margin was -1053.7% for FY2022, based on the latest annual results.

Investors sometimes search for "Ambrx Biopharma Inc. net worth" — the company's market capitalization is a separate figure from AMAM net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

AMAM net income · 4 questions

Ambrx Biopharma Inc. is not currently profitable on an annual basis. The company reported a net loss of $78.0M for FY2022.

is AMAM profitabledoes AMAM make a profitAMAM profitabilityAMAM profitable company

▸ Source: FMP /income-statement · GAAP · Ambrx Biopharma Inc. · Ambrx Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026